Myriad Genetics, SimonMed Imaging collaborate to advance precision medicine

Myriad Genetics and SimonMed Imaging announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk with RiskScore and patient education. Leveraging a custom-built Myriad tool developed in collaboration with SimonMed, the program is expected to enable affordable access to genetic testing and deliver personalized insights to better inform clinical decisions for the millions of patients and families served at SimonMed. Myriad and SimonMed will begin a phased rollout of the program in early May 2023 to patients at select SimonMed women’s imaging sites. The program is expected to be operational in all 86 of SimonMed’s women’s imaging sites by the end of this year, with the goal of supporting all SimonMed patients in their remaining 85 sites and service lines, thereafter. "Myriad’s commitment to patient access, affordability, health equity and scientific innovation directly aligns with SimonMed’s mission to better serve our communities," said Paul Diaz, president and CEO, Myriad Genetics. "With recent clinical guideline developments from a variety of professional societies regarding genetic risk assessment beginning as early as age 25-30, this collaboration is critically important to help recognize and screen younger high-risk patients and ensure they receive appropriate supplemental screening and medical management options to best manage their elevated risk."